Pregene Biopharma
China - ShenzhenPharmaceutical
Focus: Pregene Biopharma is a China-based cellular therapy and nanobody specialist focused on oncology, immunology, and hematology indications. The company operates as a pre-revenue biotech with an early-stage pipeline concentrated in CAR-T and CAR-NK cell therapies.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Pregene Biopharma
AI assessmentNot HiringNo open roles listed right now. Follow Pregene Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
18 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PRG-1801 （CAR-T against BCMA）
Lupus NephritisClinical Trials (1)
NCT06277427Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
N/AHelp build intelligence for Pregene Biopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.